Traws Pharma Inc (NASDAQ: TRAW) started the day on Wednesday, with a price decrease of -10.63% at $8.07, before settling in for the price of $9.03 at the close. Taking a more long-term approach, TRAW posted a 52-week range of $4.06-$19.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -22.90%. Meanwhile, its Annual Earning per share during the time was 58.67%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -586.00%. This publicly-traded company’s shares outstanding now amounts to $3.03 million, simultaneously with a float of $2.74 million. The organization now has a market capitalization sitting at $29.32 million. At the time of writing, stock’s 50-day Moving Average stood at $6.08, while the 200-day Moving Average is $10.46.
Traws Pharma Inc (TRAW) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Traws Pharma Inc’s current insider ownership accounts for 24.59%, in contrast to 1.12% institutional ownership.
Traws Pharma Inc (TRAW) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Traws Pharma Inc’s EPS decrease for this current 12-month fiscal period is -586.00% and is forecasted to reach -35.52 in the upcoming year.
Traws Pharma Inc (NASDAQ: TRAW) Trading Performance Indicators
Let’s observe the current performance indicators for Traws Pharma Inc (TRAW). It’s Quick Ratio in the last reported quarter now stands at 1.07. The Stock has managed to achieve an average true range (ATR) of 1.65. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 127.48.
In the same vein, TRAW’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -141.35, a figure that is expected to reach -9.55 in the next quarter, and analysts are predicting that it will be -35.52 at the market close of one year from today.
Technical Analysis of Traws Pharma Inc (TRAW)
If we take a close look at the recent performances of Traws Pharma Inc (NASDAQ: TRAW), its last 5-days Average volume was 0.18 million that shows progress from its year to date volume of 0.18 million. During the previous 9 days, stock’s Stochastic %D was recorded 14.69% While, its Average True Range was 1.82.
Raw Stochastic average of Traws Pharma Inc (TRAW) in the period of the previous 100 days is set at 26.07%, which indicates a major rise in contrast to 21.26% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 444.64% that was higher than 182.53% volatility it exhibited in the past 100-days period.
